CymaBay Therapeutics (CBAY) – Company Press Releases
-
Gilead Sciences Announces Completion of Acquisition of CymaBay
-
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
-
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
-
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
-
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
-
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
-
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
-
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
-
CymaBay Therapeutics to Present at Upcoming Investment Conferences
-
CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
-
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
-
CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
-
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
-
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
-
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
-
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
-
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
-
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
-
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update
-
CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase
-
CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023
-
CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
-
CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023
-
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
-
CymaBay Names Harish Shantharam Chief Financial Officer
-
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
-
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
-
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
-
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
-
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
-
CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
-
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
-
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
Back to CBAY Stock Lookup